Ajanta Pharma Ltd.
Snapshot View

2394.15 +66.45 ▲2.9%

29 July 2021, 04:00:00 P.M.
Volume: 12,603

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.ajantapharma.com
Financial Indicators
Market Cap 20,717.00 Cr.
Earnings per share (EPS) 75.56 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 31.68 Trailing Twelve Months Ending 2021-03
Industry PE 34.39 Trailing Twelve Months Ending 2021-03
Book Value / Share 346.12 Trailing Twelve Months Ending 2021-03
Price to Book Value 6.92 Calculated using Price: 2,394.15
Dividend Yield 0.40 Period Ending 2021-03
No. of Shares Subscribed 8.65 Cr. 86,531,770 Shares
FaceValue 2
Company Profile

Ajanta Pharma is established in 1973. Committed to 'Serve Health Care Needs Worldwide', the company produces a comprehensive range of specialty products targeting different therapeutic segments for treatment of patients, customised to each market it is present in. The company's Institutional business comprises of India Business and Africa Business. In India, company is a reliable supplier for various government bodies like Armed forces, government hospitals, canteens, stores department, etc. The product basket for India market includes multivitamins, antibiotics, eye drops, cough syrups, etc. In Africa, the company was the first Generic Company to obtain 'WHO Pre-Qualification' for Anti-Malarial product, a combination of Artemether plus Lumefantrine. It has been innovating on this product since then and has given many new variations for patient convenience and compliance.

As a part of the company’s philosophy to build sustainable and scalable business model, it set its eye on entering the world’s largest and most stringent pharmaceutical market-USA. It carved out select product portfolio which include complex technology products to get the competitive advantage in the market place. It has also made substantial investments in its R&D facilities and thereby acquired required technical and regulatory expertise to penetrate the market. It has an advanced Research & Development Centre for finished formulations and Active Pharmaceutical Ingredient (API) synthesis of different dosage forms.

Business area of the company

Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages. Its business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales. Emerging markets are the major contributors in company’s branded generic business where it is present across Asia and Africa. It has designed customised basket of products for each of these markets and serve wide range of therapeutic segments like Anti-Biotic, Anti-Malarial, Anti-Diabetic, Cardiology, Gynecology, Orthopedics, Pediatric, Respiratory & General Health products.

Awards and accreditations

  • 2011: Gold Trophy for Quality Excellence from Indian Drug Manufacturer's Association.
  • 2015: Listed in Top 100 Companies of Asia by Bio Spectrum Asia, Ranked 76th.
  • 2015: Listed in Fortune India Next 500, being 3rd largest wealth creator during last 5 years, Ranked 20th in Net Profit and 182nd in Sales.
  • 2015: Fastest wealth creator in last 5 years as per a study by Motilal Oswal.
  • 2016: Listed in ‘Fastest Growing Company in India’ and Ranked 21st by Outlook Business Magazine.
  • 2017: Ajanta listed among fastest growing pharma company, ranked 11th in revenue by Businessworld.
  • 2017: Listed among Out Performers List of Outlook Business, ranked 1st Among Stock Return.
  • 2017: Listed among ‘Forbes India Super 50 Companies’ for the 3rd year in a row.
  • 2017: Listed in BT 500 ranked 148th in Market Capitalisation, 327th in sales & 102nd in Profit.
  • 2017: Ranked 186th in Next Super 100 companies by Business India.
  • 2017: Listed as Fastest Wealth Creator for the 3rd year in a row by Motilal Oswal.
  • 2018: Listed in Fortune 500 list of Indian companies Ranked 3rd in wealth creation.
  • 2018: Top Export Performer Award' by the Federation of Indian Export Organisations.

Major events and milestones

  • 1973: Ajanta started with re-packing of generic products.
  • 1979: Launched branded OTC (Over the Counter) products.
  • 1979: First Manufacturing Facility set up in India- (Chikalthana).
  • 1986: Started production at second manufacturing facility in India-(Paithan).
  • 1989: Launched block buster OTC product '30+' in India.
  • 1992: Foray in international market.
  • 1995: Established subsidiary in Mauritius with manufacturing facility.
  • 2000: Got listed on National Stock Exchange (NSE) and Bombay Stock Exchange (BSE).
  • 2005: Strategic shift from OTC to Innovative Specialised Prescription Products in Ophthal, Dermatology & Cardiology.
  • 2007: Set-up dedicated fully equipped R&D facility in Mumbai.
  • 2009: Bought a manufacturing facility at Chitegaon to fuel the company's growth.
  • 2009: API facility set up in Waluj for captive consumption.
  • 2009: First Generic Company in the world to get WHO Geneva Pre-qualification for Anti-Malarial Drug.
  • 2010: Entered Philippines market with unique product portfolio through Ajanta Pharma Philippines Inc.
  • 2011: Emerged as a strong speciality player in domestic market in Ophthalmology, Dermatology and Cardiology with many brands holding leadership positions.
  • 2012: Ranked among the Top 10 Pharma companies in Franco Africa.
  • 2013: Began Sales in the USA.
  • 2014: Second Dedicated R&D centre set up in Kandivli for India and Emerging Markets.
  • 2014: Inaugurated a New Facility in Dahej, Bharuch, Gujarat, India.
  • 2015: Launch of Montelukast lR Tablets and Chewable Tablets.
  • 2015: Launch of Montelukast Sodium Oral Granules.
  • 2016: USFDA Approval for Almotriptan Malate Tablets.
  • 2017: Inaugurated & commissioned first phase at a New Facility in Guwahati, Assam, India.
  • 2017: Dahej facility receives successful US FDA approval.
  • 2017: Launch of Eletriptan Hydrobromide tablets in US market. 
  • 2017: USFDA approval for Entacapone tablets. 
  • 2017: Approval and launch of Clonidine Hydrochloride extended release tablets.
  • 2018: Commissioned Ajanta's 1st ever Derma facility in Guwahati.
  • 2019: New manufacturing facility for oral solid inaugurated at Pithampur.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+2.85%
1 Week
+13.32%
1 Month
+14.89%
3 Month
+26.66%
6 Month
+35.45%
1 Year
+60.73%
2 Year
+165.49%
5 Year
+34.71%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 32.46 47.47 43.24 40.93 36.77 25.98 18.07 19.32 23.38
Return on Capital Employed (%) 38.57 54.52 56.43 51.59 45.72 34.49 23.84 27.44 32.20
Return on Assets (%) 16.40 28.05 29.57 31.66 30.69 22.06 14.52 14.44 17.03

Balance Sheet View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Shh. Funds 393 593 841 1,191 1,568 2,041 2,245 2,599 2,996
Non Curr. Liab. 102 81 56 29 9 39 162 228 275
Curr. Liab. 222 275 250 260 247 346 498 746 839
Minority Int.
Equity & Liab. 718 949 1,146 1,479 1,823 2,426 2,906 3,572 4,109
Non Curr. Assets 349 429 513 716 973 1,202 1,605 1,791 1,891
Curr. Assets 369 520 633 763 851 1,224 1,301 1,781 2,218
Misc. Exp. not W/O
Total Assets 718 949 1,146 1,479 1,823 2,426 2,906 3,572 4,109

Profit Loss View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 931 1,208 1,474 1,734 1,983 2,126 2,055 2,588 2,890
Other Income 6 14 17 21 24 24 21 92 26
Total Income 936 1,222 1,490 1,755 2,007 2,150 2,076 2,680 2,916
Total Expenditure -706 -840 -968 -1,147 -1,296 -1,467 -1,489 -1,905 -1,891
PBIDT 230 382 522 608 711 683 588 776 1,025
Interest -19 -9 -6 -5 -1 0 -1 -12 -8
Depreciation -34 -44 -52 -44 -61 -60 -72 -96 -116
Taxation -65 -96 -146 -143 -141 -154 -127 -196 -246
Exceptional Items -8 -4
PAT 112 234 310 416 507 469 387 468 654

Cash Flow View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 234 212 279 326 609 281 375 457 576
Cash Fr. Inv. -104 -188 -158 -209 -383 -256 -223 -224 -282
Cash Fr. Finan. -104 -20 -105 -117 -202 0 -147 -129 -318
Net Change 26 4 16 0 24 25 4 104 -24
Cash & Cash Eqvt 34 39 54 41 66 91 95 199 178

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 70.52 70.51 70.51 70.50 70.51 70.51 70.34 70.34 70.34
Public 29.48 29.49 29.49 29.50 29.49 29.49 29.66 29.66 29.66
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 13.37 17.77 16.86 17.29 16.15 16.06 15.17 15.49 14.95

Announcements View Details

Thu, 29 Jul 2021
Outcome Of Board Meeting
At the Board meeting held today the Board has inter-alia approved and taken on record Unaudited Financial results for the quarter ended 30th June 2021. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we enclose herewith the following:
i. Press Release being issued on the Results for the quarter ended 30th June 2021;
ii. Unaudited Consolidated Financial Results for the quarter ended 30th June 2021;
iii. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Consolidated Financial Results for the quarter ended 30th June 2021;
iv. Unaudited Standalone Financial Results for the quarter ended 30th June 2021;
v. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Standalone Financial Results for the quarter ended 30th June 2021;
vi. Investors presentation.
Fri, 23 Jul 2021
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Issue of Duplicate Share Certificate under Regulation 39(3) of SEBI (LODR) Regulations 2015.
Thu, 22 Jul 2021
Schedule Of Earnings Conference Call Post Board Meeting
Pursuant to Regulation 30 of the SEBI (Listing obligations and Disclosure Requirements) Regulations 2015 we are enclosing herewith the schedule of Earnings conference call to be
held on 29th July 2021 post Board meeting.

This is for your information and records please.

Technical Scans View Details

Thu, 29 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Increasing Relative Strength - Benchmark index Increasing Relative Strength - Benchmark index
Strongly Outperforming Sectoral Index Strongly Outperforming Sectoral Index

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,733.23 703.00 +2.2%
Divi's Laboratories Ltd. 128,656.69 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. 77,707.65 4,672.65 -1.2%
Cipla Ltd. 71,170.06 883.10 -0.8%
Cadila Healthcare Ltd. 58,547.84 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. 58,067.43 4,028.55 0.0%
Aurobindo Pharma Ltd. 53,214.94 908.25 -0.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.11 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2021-03 64.84 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 44.73 4,672.65 -1.2%
Cipla Ltd. Consolidated 2021-03 29.59 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 27.44 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 386.19 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2021-03 9.98 908.25 -0.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2021-03 13.84 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.35 4,672.65 -1.2%
Cipla Ltd. Consolidated 2021-03 3.88 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 4.51 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.64 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.43 908.25 -0.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,672.65 -1.2%
Cipla Ltd. Consolidated 2020-03 0.18 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 908.25 -0.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,672.65 -1.2%
Cipla Ltd. Consolidated 2020-03 10.09 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 908.25 -0.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,672.65 -1.2%
Cipla Ltd. Consolidated 2020-03 12.53 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 908.25 -0.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,672.65 -1.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 908.25 -0.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 703.00 +2.2%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,843.80 -1.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,672.65 -1.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 883.10 -0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 572.00 -0.9%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,028.55 0.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 908.25 -0.8%